Cystic Fibrosis Foundation issued the following clinical trial alerts in October.
October 15, 2020
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis
Status: Completed with Results
Description: This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
Age: 6 Years to 11 Years
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40% or greater
Number of Visits: 9
Length of Participation: 32 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03691779
Status: Completed with Results
Description: This study evaluated the effectiveness of inhaled molgramostim (Molgradex), a drug intended to treat nontuberculous mycobacterial (NTM) infections in the lungs of people with CF.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 30% or greater
Number of Visits: 19
Length of Participation: 72 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03597347